Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gelsectan in Diarrhea-predominant Irritable Bowel Syndrome
NCT07000383Recruiting
- Sponsor
- University Medical Center Ho Chi Minh City
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Peptides, Device-based Delivery
- Countries
- 1
01
Overview
Randomised, open-label trial of Gelsectan in Irritable bowel syndrome with diarrhea (IBS-D) (3 arms), sponsored by University Medical Center Ho Chi Minh City. Primary endpoint: Clinical remission of IBS-D symptoms at 2 months. Started Jun 2025; status: recruiting.
02
Drugs
Gelsectan
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT07000383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07000383.